Cell Death Discovery

OCT 16, 2026 · JOURNAL ARTICLE

Targeting the AR-UBE2C axis unleashes autophagy-associated cell death to overcome intrinsic resistance to PI3K Inhibition in AR-overexpressed breast and prostate cancers

Cell Death Discovery

Abstract Luminal androgen receptor (LAR) subtype triple-negative breast cancer (TNBC) overexpresses AR, making anti-androgen receptor therapy a viable strategy. The PI3K/AKT/mTOR s

OCT 15, 2026 · JOURNAL ARTICLE

SRPX2 aggravates tumor progression and immune resistance through TGFBR2-mediated epithelial–mesenchymal transition in colorectal cancer

Cell Death Discovery

Abstract Colorectal cancer (CRC) metastasis presents a formidable clinical challenge, particularly for microsatellite stability (MSS) subtypes that show limited response to current

OCT 8, 2026 · JOURNAL ARTICLE

Small mitochondria-targeting compound SMIP004 selectively eliminates therapy-induced senescent tumor cells by blocking AMPK-dependent PDHA stabilization and improves the outcomes of chemotherapy

Cell Death Discovery

Abstract Therapy-induced senescence (TIS) contributes to tumor recurrence and metastasis. Selective elimination of TIS cells by senolytics would be beneficial for cancer treatment.

OCT 6, 2026 · JOURNAL ARTICLE

Harnessing the cooperative function of duplex from pre-miR-16 hairpin to simultaneously inhibit VEGF and hypoxia pathways in human non-small cell lung cancer

Cell Death Discovery

Abstract Resistance to anti-angiogenic therapy remains a major obstacle in non–small cell lung cancer (NSCLC). Although bevacizumab effectively neutralizes VEGFA and suppresses neo

SEP 24, 2026 · JOURNAL ARTICLE

Resveratrol ameliorates diabesity-associated insulin resistance and hepatic steatosis via mTORC1 downregulation

Cell Death Discovery

Abstract Type 2 diabetes (T2DM) is characterized by insulin resistance and, as a compensatory mechanism, an increase in pancreatic β-cell mass. Obesity, a major risk factor for T2D

SEP 17, 2026 · JOURNAL ARTICLE

Anthracycline and antimetabolite, trigger distinct resistance mechanisms in TP53mut AML

Cell Death Discovery

Acute myeloid leukemia (AML) is a highly heterogeneous and extremely aggressive form of blood cancer. Despite recent advances, AML continues to be a challenging disease to treat; t

SEP 16, 2026 · JOURNAL ARTICLE

ESAM reduces sensitivity to anti-HER2 therapy in HER2-positive breast cancer by activating the mTOR pathway

Cell Death Discovery

Abstract Despite improved survival rates with dual trastuzumab and pertuzumab therapy, patients with HER2-positive breast cancer frequently experience disease progression due to in

SEP 14, 2026 · JOURNAL ARTICLE

HAT1 regulates glioblastoma cell proliferation and membrane lipid remodeling through ALDH2

Cell Death Discovery

Abstract Glioblastoma (GBM) is the most aggressive and lethal form of primary brain cancer in adults, characterized by rapid cell proliferation, resistance to therapy, and poor pat